noninvas
diagnost
approach
crucial
evalu
sever
liver
diseas
treatment
decis
assess
drug
efficaci
studi
evalu
plasma
proteom
profil
via
ntermin
isotop
tag
strategi
coupl
liquid
chromatographyfouri
transform
ion
cyclotron
reson
mass
spectrometri
measur
detect
liver
fibrosi
stage
pool
plasma
differ
liver
fibrosi
stage
assess
advanc
current
goldstandard
liver
biopsi
quantit
analyz
total
plasma
protein
found
dysregul
fibrogenesi
process
find
constitut
valuabl
candid
plasma
biomark
bank
followup
analysi
valid
result
fibronectin
western
blot
reconfirm
massbas
data
ingenu
pathway
analysi
show
four
type
metabol
network
function
effect
liver
fibrosi
diseas
chronic
hepat
b
patient
consequ
quantit
proteom
via
ntermin
acetyl
isotop
label
techniqu
provid
effect
use
tool
screen
plasma
candid
biomark
liver
fibrosi
quantit
monitor
fibrogenesi
process
chb
patient
discov
mani
new
valuabl
candid
biomark
diagnosi
liver
fibrosi
also
partli
identifi
mechan
involv
liver
fibrosi
diseas
result
provid
clearer
understand
liver
fibrosi
pathophysiolog
also
hope
lead
improv
clinic
diagnosi
treatment
quantit
proteom
liver
fibrosi
biomark
plasma
hepat
b
viru
citat
li
l
liu
x
wei
l
et
al
plasma
biomark
screen
liver
fibrosi
ntermin
isotop
tag
strategi
million
individu
china
liver
fibrosi
common
respons
chb
infect
might
result
potenti
lethal
sequela
progress
cirrhosi
patient
compens
cirrhosi
progress
hepat
decompens
hepatocellular
carcinoma
within
five
year
patient
respect
approxim
death
occur
year
worldwid
consequ
fulmin
hepat
failur
cirrhosi
hepatocellular
carcinoma
liver
diseas
incur
diseas
liver
fibrosi
cirrhosi
revers
accur
diagnosi
crucial
evalu
sever
diseas
treatment
decis
assess
drug
efficaci
clinic
alway
difficult
make
noninvas
diagnosi
liver
fibrosi
liver
biopsi
current
goldstandard
procedur
assess
degre
fibrosi
sever
disadvantag
costli
procedur
poor
patient
complianc
discomfort
patient
risk
poorli
standard
collect
liver
tissu
limit
use
dynam
surveil
followup
consid
limit
accur
reliabl
noninvas
method
assess
sever
hepat
fibrosi
urgent
need
plasma
biomark
offer
attract
altern
liver
biopsi
contain
consider
inform
liver
condit
less
invas
biopsi
may
allow
dynam
calibr
fibrosi
may
econom
sever
marker
marker
set
shown
promis
toward
goal
none
fulli
satisfi
requir
especi
accur
stage
liver
fibrosi
chronic
hepat
b
chb
patient
therefor
suitabl
plasma
marker
high
specif
good
sensit
requir
noninvas
monitor
liver
fibrosi
progress
proteom
use
determin
express
dynam
mani
protein
especi
suitabl
explor
diseas
biomark
comparison
proteom
diseas
control
plasma
sampl
shown
suitabl
approach
discov
plasma
biomark
liver
diseas
quantit
proteom
techniqu
base
stabl
isotop
label
increasingli
appli
biomark
studi
ntermin
acetyl
isotop
label
techniqu
show
great
potenti
biomark
detect
highthroughput
identif
accur
quantif
protein
well
simpl
procedur
lead
edg
liquid
chromatographyfouri
transform
ion
cyclotron
reson
mass
spectrometri
lcfticrm
technolog
superior
sensit
power
measur
also
contribut
plasma
biomark
detect
therefor
techniqu
select
strategi
studi
base
histolog
chronic
liver
diseas
studi
design
explor
candid
plasma
biomark
correl
stage
patholog
quantit
proteom
techniqu
ntermin
acetyl
label
aim
investig
new
candid
plasma
biomark
accur
noninvas
diagnosi
liver
fibrosi
chb
patient
improv
stage
liver
diseas
assess
effect
treatment
predict
diseas
progress
liver
biopsi
obtain
consecut
chb
patient
peopl
hospit
peke
univers
militari
hospit
china
studi
approv
local
ethic
committe
written
inform
consent
obtain
particip
clinic
hematolog
biochem
data
record
patient
within
one
week
liver
biopsi
includ
patient
serum
posit
hepat
b
surfac
antigen
hepat
b
eantigen
hepat
b
viru
dna
least
six
month
serum
level
alanin
aminotransferas
two
time
upper
limit
normal
within
six
month
liver
biopsi
prior
therapi
antivir
immunoregul
drug
patient
posit
laboratori
test
human
immunodefici
viru
posit
serum
antihepat
c
viru
antihcv
andor
hcv
rna
decompens
liver
diseas
alcohol
liver
diseas
suspect
autoimmun
diseas
antinuclear
antibodi
titer
greater
serum
creatinin
time
greater
normal
inadequ
hematolog
function
exclud
select
patient
receiv
liver
biopsi
direct
ultrasonographi
within
one
week
inclus
quickcut
compani
japan
menghini
needl
g
use
procedur
biopsi
specimen
fix
formalin
routin
embed
paraffin
tissu
section
process
hematoxylin
eosin
masson
trichrom
reticular
fiber
stain
appendix
figur
electron
version
minimum
length
least
cm
liver
biopsi
least
six
portal
tract
requir
diagnosi
five
fibrosi
stage
determin
use
scheuer
classif
stage
fibrosi
stage
enlarg
fibrot
portal
tract
stage
periport
portalport
septa
intact
architectur
stage
fibrosi
architectur
distort
obviou
cirrhosi
stage
cirrhosi
liver
fibrosi
consid
signific
spread
beyond
portal
tract
stage
wherea
consid
insignific
absent
restrict
portal
tract
stage
respect
section
blindli
independ
assess
two
pathologist
hospit
detail
inform
patient
characterist
sex
age
type
diseas
shown
tabl
appendix
tabl
electron
version
obtain
inform
consent
collect
ml
fast
blood
sampl
venipunctur
bd
vacutain
edta
bd
bioscienc
franklin
lake
nj
usa
plasma
obtain
centrifug
blood
min
supernat
transfer
fresh
microtub
axygen
scientif
inc
usa
cen
tabl
electron
version
trifug
min
store
analysi
patient
fast
least
h
blood
sampl
remov
albumin
immunoglobulin
human
plasma
sampl
treat
remov
kit
merck
compani
germani
accord
manufactur
instruct
appendix
figur
electron
version
treat
sampl
measur
nm
protein
concentr
protein
dc
kit
biorad
usa
base
lowri
method
evalu
reproduc
effect
remov
treat
sampl
separ
sodium
dodecylsulf
polyacrylamid
gel
electrophoresi
sdspage
protein
per
lane
stain
syprorubi
biorad
main
procedur
research
shown
figur
individu
plasma
includ
measur
protein
concentr
protein
dc
kit
biorad
individu
plasma
group
pool
equal
follow
fraction
repres
correspond
fibrosi
stage
plasma
five
group
pool
equal
intrastandard
p
group
pool
treat
plasma
compar
intrastandard
p
correspond
ratio
valu
use
correspond
protein
quantifi
data
total
treat
plasma
protein
group
p
boil
sdspage
sampl
buffer
resolv
sdspage
gel
stain
coomassi
blue
group
gel
lane
neighbor
intrastandard
gel
lane
excis
parallel
manner
gel
divid
horizont
section
total
process
separ
tryptic
digest
describ
appendix
figur
electron
version
gel
particl
wash
twice
suitabl
volum
immers
gel
particl
mmol
l
ammonium
figur
schemat
diagram
human
plasma
quantit
proteom
analysi
use
ntermin
acetyl
label
approach
pool
plasma
sampl
along
intrastandard
intra
standard
plasma
pool
plasma
includ
studi
similarli
process
fraction
sdspage
combin
differenti
isotop
label
individu
fraction
analyz
lcmsm
data
process
use
msaq
acetonitril
sigma
usa
supernat
remov
discard
wash
destain
gel
particl
dri
min
speedvac
thermo
electron
usa
rehydr
mmol
l
ammonium
bicarbon
buffer
contain
trypsin
min
gel
overlaid
mmol
l
ammonium
bicarbon
buffer
incub
h
peptid
extract
trifluoroacet
acid
tfa
tfa
supernat
remov
step
save
tube
peptid
dri
speedvac
store
group
lysin
guanidin
describ
previous
modif
equal
volum
mol
l
omethylisourea
dissolv
mol
l
carbon
buffer
adjust
ph
mol
l
naoh
ad
peptid
mixtur
incub
h
solut
adjust
back
ph
mol
l
hcl
acetyl
total
borat
buffer
ad
solut
mainten
ph
valu
anhydrid
dilut
mol
l
tetrahydrofuran
ad
guanidin
peptid
amount
dilut
acet
anhydrid
use
per
digest
peptid
acetyl
reaction
perform
room
temperatur
h
nhydroxylamin
use
hydrolyz
ester
form
acetyl
reaction
incub
min
ph
result
solut
desalt
column
lyophil
store
use
result
plasma
peptid
analyz
use
linear
quadrupol
iontrap
fouriertransform
ioncyclotron
reson
ltqft
mass
spectromet
thermo
electron
san
jose
ca
usa
coupl
agil
nanoflow
liquid
chromatographi
system
revers
phase
trap
column
intern
mm
long
column
connect
sixport
columnswitch
valv
onlin
desalt
tip
column
biobas
particl
size
intern
cm
long
column
acquir
raw
file
convert
dta
file
biowork
dta
file
merg
one
mgf
format
file
script
name
mergepl
mgf
file
search
intern
protein
index
ipi
human
ftp
ftpebiacukpubdatabasesipi
inhous
mascot
version
da
da
peptid
nterminu
guanidin
lysin
residu
da
cystein
carbamidomethyl
da
set
fix
modif
maxim
allow
misscleavag
site
two
mass
toler
peptid
fragment
ion
da
respect
least
confid
identifi
peptid
score
greater
identifi
protein
least
one
uniqu
posit
peptid
share
protein
base
mascot
result
monoisotop
peak
ratio
heavylabel
peptid
lightlabel
peptid
automat
calcul
graphic
user
interfac
program
call
mass
spectrometri
quantif
acetyl
label
msaq
develop
hous
basic
quantit
inform
intens
pair
parent
ion
lightor
heavylabel
peptid
ms
full
scan
peptid
pair
accur
extract
match
mz
parent
ion
peak
ms
full
scan
around
msm
scan
time
intens
ratio
label
peptid
pair
comput
isotop
peak
lightlabel
peptid
might
overlap
monoisotop
peak
heavylabel
peptid
especi
mass
greater
da
observ
ratio
could
larger
true
ratio
accord
theori
isotop
distribut
calcul
polynomi
algorithm
overlap
portion
subtract
step
mention
mean
standard
deviat
ratio
pair
peptid
calcul
use
final
quantit
ratio
peptid
maintain
data
qualiti
minim
signalnois
sn
pair
set
greater
two
read
raw
file
xcalibur
develop
kit
xdk
api
function
predomin
interact
network
differenti
express
protein
conduct
use
ipa
webdeliv
applic
wwwingenuitycom
biolog
function
assign
network
rank
accord
signific
biolog
function
network
fischer
exact
test
use
calcul
pvalu
sampl
run
sdspage
gel
transfer
onto
polyvinyliden
difluorid
membran
transblot
electrophoresi
transfer
cell
biorad
membran
block
overnight
mmol
l
trishcl
mmol
l
nacl
ph
tbst
contain
skim
milk
primari
antibodi
use
fibronectin
antibodi
dilut
santa
cruz
biotechnolog
usa
membran
incub
room
temperatur
h
primari
antibodi
wash
three
time
incub
horseradish
peroxidaseconjug
secondari
antibodi
dilut
santa
cruz
biotechnolog
h
room
temperatur
visual
immunoreact
protein
accomplish
use
enhanc
chemiluminesc
reagent
santa
cruz
biotechnolog
membran
expos
xray
film
scan
scanner
biorad
quantifi
total
plasma
protein
among
protein
ratio
maxmin
quantifi
express
liver
fibrosi
stage
dysregul
liver
fibrosi
stage
provid
valuabl
refer
biomark
bank
liver
fibrosi
detect
data
list
appendix
tabl
electron
version
mass
spectra
select
peptid
shown
figur
mass
spectra
select
peptid
attach
appendix
figur
electron
version
detail
inform
quantit
data
list
appendix
tabl
valid
reliabl
nit
ntermin
isotop
tag
result
one
identifi
protein
fibronectin
select
examin
western
blot
protein
report
hcv
patient
report
chb
patient
especi
liver
fibrosi
stage
show
similar
express
data
nit
proteom
techniqu
reconfirm
proteom
data
well
potenti
clinic
use
figur
search
diseasespecif
biomark
human
plasma
gain
increas
attent
signific
advanc
proteom
technolog
potenti
discov
novel
diseas
biomark
noninvas
plasma
biomark
diagnosi
hepat
fibrosi
becom
popular
provid
consider
inform
crucial
evalu
sever
diseas
treatment
decis
assess
drug
efficaci
current
avail
noninvas
method
assess
liver
fibrosi
chb
patient
imperfect
lack
accuraci
reliabl
therefor
reliabl
biomark
requir
solv
issu
base
high
mass
accuraci
sensit
instrument
ltqft
stabl
isotop
label
techniqu
produc
reliabl
result
quantit
proteom
analysi
advantag
simpl
label
procedur
low
cost
full
label
abil
protein
high
accuraci
sensit
ntermin
isotop
label
technolog
reliabl
power
strategi
biomark
analysi
quantifi
total
protein
base
aim
stringent
screen
high
confid
chose
protein
markedli
dysregul
five
group
least
two
peptid
quantifi
protein
result
differ
protein
found
quantit
analysi
among
liver
fibrosi
stage
abl
construct
reliabl
dataset
detect
liver
fibrosi
liver
fibrosi
dynam
multifactori
process
involv
complex
interact
within
mani
type
cell
type
process
disrupt
accumul
sever
distinct
extracellular
matrix
ecm
protein
hepat
b
caus
liver
fibrosi
direct
cytopath
mean
direct
indirect
interact
hepat
stellat
cell
hsc
well
activ
immun
system
plasma
protein
contain
mani
messag
fibrogenesi
process
directli
indirectli
studi
significantli
dysregul
protein
relat
sever
type
mechan
hsc
dysfunct
immun
factor
impair
lipid
metabol
protein
synthesi
liver
hematolog
system
develop
candid
protein
discuss
protein
relat
hsc
dysfunct
hsc
play
central
role
fibrogenesi
process
hsc
dysfunct
reflect
sever
aspect
gelsolin
one
candid
protein
lf
diagnosi
studi
actinfrag
cytoplasm
protein
play
import
role
hsc
growth
regul
suggest
involv
cell
motil
inhibit
apoptosi
protect
role
liver
tissu
gelsolin
level
decreas
liver
injuri
liver
cancer
found
protein
downregul
express
stage
suggest
liver
cell
apoptosi
intensifi
indic
potenti
valu
clinic
diagnosi
fibronectin
glycoprotein
major
sourc
hepatocyt
kupffer
cell
endotheli
cell
mani
biolog
function
includ
adhes
cell
immun
blood
coagul
platelet
aggreg
report
downregul
liver
cirrhosi
hcv
patient
howev
sensibl
accuraci
liver
fibrosi
stage
especi
chb
patient
unknown
found
fibronectin
downregul
stage
show
potenti
power
liver
fibrosi
stage
ii
protein
relat
liver
synthesi
function
protein
synthesi
mostli
carri
liver
damag
liver
includ
liver
fibrosi
diseas
caus
hbv
reflect
plasma
protein
hemopexin
plasma
glycoprotein
express
liver
synthes
lower
rate
fetal
liver
adult
hemopexin
essenti
protect
splenomegali
liver
fibrosi
result
intravascular
hemolysi
studi
observ
downregul
express
hemopexin
suggest
dysfunct
role
liver
fibrosi
diseas
vitronectin
multifunct
plasma
glycoprotein
produc
hepatocyt
extens
studi
cell
adhes
molecul
may
play
import
role
progress
liver
diseas
andor
hepat
fibrosi
collagenbind
domain
found
vitronectin
upregul
studi
suggest
could
potenti
biomark
fibrogenesi
orosomucoid
glycoprotein
polymorph
acutephas
reactant
immunosuppress
properti
found
significantli
increas
patient
differ
type
carcinoma
previou
investig
suggest
orosomucoid
acutephas
reactant
may
act
block
factor
protect
tumor
cell
immunolog
attack
therebi
contribut
immun
escap
tumor
requir
maintain
high
capillari
permselect
requir
normal
homeostasi
studi
observ
orosomucoid
tend
upregul
liver
fibrosi
develop
result
help
detect
liver
fibrosi
well
determin
molecular
mechan
amyloid
p
compon
plasma
protein
possibl
role
liver
protein
synthesi
might
use
marker
liver
involv
amyloid
p
compon
plasma
level
degre
diseas
activ
hepat
impair
close
correl
patient
liver
diseas
current
studi
amyloid
p
compon
express
decreas
result
may
help
routin
judgment
ficolin
synthes
liver
play
import
role
lectin
pathway
complement
system
downregul
express
follow
fibrogenesi
process
potenti
make
suitabl
biomark
studi
found
isoform
kininogen
protein
downregul
stage
iii
protein
relat
immun
factor
chronic
viral
diseas
liver
associ
chang
immun
reaction
mediat
immun
effector
mechan
immunoglobulin
one
main
protein
immun
respons
express
differ
differ
diseas
recent
report
appear
correl
degre
fibrosi
differ
glycosyl
studi
also
observ
sever
type
immunoglobulin
protein
peptid
relat
differ
liver
fibrosi
stage
differ
express
protein
may
relat
natur
histori
diseas
may
use
noninvas
detect
fibrosi
cirrhosi
found
immunerel
protein
protein
complement
factor
show
dysregul
express
liver
fibrosi
develop
suggest
play
import
role
particip
altern
pathway
hbv
diseas
iv
protein
relat
lipid
metabol
sever
type
apolipoprotein
clinic
use
noninvas
biomark
liver
fibrosi
diagnosi
hcv
patient
nonalcohol
fatti
liver
diseas
carcinoma
one
type
pathway
affect
diseas
develop
apolipoprotein
enter
cell
via
lowdens
lipoprotein
receptor
identifi
apolipoprotein
group
includ
apolipoprotein
aiv
b
e
l
show
dysregul
express
fibrogenesi
process
indic
lipid
metabol
play
import
role
fibrogenesi
develop
chb
patient
v
protein
relat
develop
hematolog
system
hemoglobin
erythrocyt
sourc
iron
accumul
liver
mediat
liver
cell
damag
viral
hepat
use
seldi
surfac
enhanc
laser
desorpt
ioniz
system
hemoglobin
found
correl
liver
fibrosi
chb
patient
found
three
type
subunit
hemoglobin
could
use
differenti
differ
stage
fibrosi
chb
patient
reninangiotensin
system
regul
fibrosi
princip
effector
molecul
reninangiotensin
angiotensinogen
mainli
produc
liver
play
multirol
human
hsc
liver
cirrhosi
patient
chronic
hepat
b
studi
found
protein
express
upregul
stage
compar
liver
fibrosi
stage
chb
patient
vi
protein
group
enzym
sever
type
enzym
use
biomark
diagnosi
liver
diseas
aldehyd
dehydrogenas
previous
report
play
pathogenet
role
develop
alcohol
liver
diseas
current
studi
downregul
stage
suggest
function
effect
hepat
b
diseas
well
potenti
diagnosi
esteras
degrad
oxid
lipid
associ
hepat
diseas
found
express
upregul
make
protein
suitabl
candid
marker
monitor
lf
process
vii
candid
protein
among
candid
protein
sever
dysregul
fibrogenesi
process
plasma
protein
unknown
function
report
biomark
diseas
includ
microbi
infect
cancer
studi
upregul
stage
would
valuabl
candid
protein
lf
diagnosi
serpin
peptidas
inhibitor
report
biomark
sever
diseas
recent
report
also
show
biomark
potenti
fibrosi
progress
hcv
patient
differ
type
serpin
peptidas
inhibitor
clade
member
clade
c
f
g
studi
show
increas
express
stage
suggest
potenti
liver
fibrosi
detect
clusterin
report
biomark
sever
diseas
overexpress
occur
variou
human
malign
current
studi
clusterin
show
dysregul
express
use
inform
liver
fibrosi
analysi
transthyretin
primarili
synthes
choroid
plexu
bind
betaamyloid
peptid
sever
diseas
associ
protein
may
also
potenti
biomark
stage
chb
patient
necessari
mention
protein
molecular
weight
cdna
code
hypothet
protein
also
show
close
correl
lf
stage
chb
patient
studi
requir
valid
potenti
valu
detail
also
note
identifi
protein
differ
isoform
truncat
form
posttransl
modif
phosphoryl
therefor
come
test
verif
protein
also
carri
studi
provid
insight
possibl
compensatori
mechan
regard
process
liver
fibrosi
well
valuabl
refer
clinic
diagnosi
ipa
result
suggest
potenti
mechan
fibrogenesi
ipa
webbas
softwar
use
identifi
biolog
mechan
pathway
function
relev
experiment
dataset
interest
http
wwwingenuitycom
allow
profil
data
analyz
systemat
way
use
known
pathway
repres
protein
undergo
chang
identifi
protein
map
onto
network
avail
ingenu
databas
use
upload
file
ipi
protein
four
pathway
construct
ipa
appendix
figur
tabl
electron
version
relat
cellular
assembl
organ
develop
develop
function
hepat
system
neurolog
diseas
develop
function
hematolog
system
cardiac
damag
cardiovascular
diseas
skelet
muscular
disord
pathogenesi
fibrosi
cirrhosi
chronic
viral
hepat
multifactori
involv
recurr
liver
injuri
sustain
inflamm
differenti
activ
ecmproduc
cell
liver
main
site
synthesi
releas
plasma
protein
infect
hbv
plasma
protein
like
quantit
qualit
affect
ipa
analysi
differenti
express
protein
could
contribut
comprehens
mechan
fibrogenesi
chb
patient
therefor
studi
requir
protein
relat
pathway
grow
consensu
panel
marker
abl
suppli
specif
sensit
individu
marker
lack
integr
test
fingerprint
mani
differenti
protein
identifi
studi
may
better
reflect
patient
statu
one
marker
alon
exampl
haptoglobin
hemoglobin
iglc
immunoglobulinfre
light
chain
may
coupl
togeth
lf
diagnosi
reliabl
liver
fibrosi
diagnosi
mani
protein
could
also
detect
parallel
followup
analysi
howev
mani
candid
protein
found
studi
commerci
avail
kit
detect
therefor
proteinchip
technolog
multipl
reaction
monitor
mass
spectrometri
technolog
could
possibl
perform
simultan
singl
experi
detect
quantifi
specif
protein
peptid
plasma
patient
liver
fibrosi
determin
degre
hepat
fibrosi
number
studi
shown
feasibl
approach
studi
requir
valid
use
model
chb
patient
prospect
manner
greater
number
valid
plasma
sampl
candid
biomark
also
test
chb
patient
larg
scale
suitabl
verif
method
enzymelabel
immunosorb
assay
multipl
reaction
monitor
determin
gener
applic
fibrosi
stage
ultim
potenti
plasma
proteom
noninvas
marker
fibrosi
cirrhosi
overal
studi
ntermin
isotop
tag
strategi
reliabl
costeffect
undemand
procedur
highthroughput
proteom
experi
show
exist
new
candid
marker
fibrosi
progress
chb
patient
data
constitut
valuabl
refer
provid
new
opportun
better
followup
hbvinfect
patient
link
mechanist
molecular
event
underli
liver
fibrosi
diseas
detect
ultim
biomark
could
aid
clinician
diagnos
develop
liver
fibrosi
elimin
need
liver
biopsi
allow
earli
treatment
monitor
fibrosi
develop
therapi
